1-乙基-1,2,3,4-四氢-1,5-萘啶 | 381227-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-乙基-1,2,3,4-四氢-1,5-萘啶
• 英文名称: 1-Ethyl-1,2,3,4-tetrahydro-1,5-naphthyridine
• 英文别名: 1-ethyl-3,4-dihydro-2H-1,5-naphthyridine
• CAS: 381227-88-9
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: XEINHKLQPNDABT-UHFFFAOYSA-N

物化性质

• 沸点：
  275.8±20.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-乙基-1,2,3,4-四氢-1,5-萘啶 在 Rh/Al₂O₃ sodium hydroxide 、 氢气 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、6.89 MPa 条件下， 生成 N,N'-diethyl-1,5-diazadecalin
  参考文献：
  名称：

  Synthesis and conformational properties of N-monoalkyl 1,5-diaza-cis-decalins

  摘要：

  N-Monoalkyl 1,5-diaza-cis-decalins were synthesized in high yield and purity by derivatization of tetrahydronaphthyridine followed by reduction to the saturated system. The position of the conformational equilibrium between the chair-chair inversion forms of a series of four N-monoalkyl of 1,5-diaza-cis-decalins was measured and was directly related to the size of the N-alkyl group. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01344-2
• 作为产物：
  描述：

  1,2,3,4-四氢-1,5-萘啶 在 硼烷四氢呋喃络合物 作用下， 生成 1-乙基-1,2,3,4-四氢-1,5-萘啶
  参考文献：
  名称：

  Synthesis and conformational properties of N-monoalkyl 1,5-diaza-cis-decalins

  摘要：

  N-Monoalkyl 1,5-diaza-cis-decalins were synthesized in high yield and purity by derivatization of tetrahydronaphthyridine followed by reduction to the saturated system. The position of the conformational equilibrium between the chair-chair inversion forms of a series of four N-monoalkyl of 1,5-diaza-cis-decalins was measured and was directly related to the size of the N-alkyl group. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01344-2

文献信息

• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• [EN] TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY<br/>[FR] COMPOSÉS TRICYCLIQUES POUR DÉGRADER DES NÉO-SUBSTRATS POUR UNE THÉRAPIE MÉDICALE
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022081927A1

  公开（公告）日：2022-04-21

  The invention provides tricyclic compounds that degrade neosubstrates for use in the treatment of disorders described herein, including, for example, abnormal cellular proliferation, neurodegenerative diseases, and autoimmune diseases.

  本发明提供了三环化合物，用于治疗本文所述的疾病，包括但不限于异常细胞增殖、神经退行性疾病和自身免疫性疾病，这些化合物可以降解新的底物。
• SHP2 phosphatase inhibitors and methods of use thereof
  申请人：Relay Therapeutics, Inc.

  公开号：US10934302B1

  公开（公告）日：2021-03-02

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

  本公开涉及新型化合物及其药物组合物，以及用本公开的化合物和组合物抑制SHP2磷酸酶活性的方法。本公开进一步涉及但不限于用本公开的化合物和组合物治疗与 SHP2 失调相关的疾病的方法。
• Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：US20210393623A1

  公开（公告）日：2021-12-23

  The present invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, the present invention provides a pharmaceutical composition comprising the said compound.
• SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Relay Therapeutics, Inc.

  公开号：US20220315586A1

  公开（公告）日：2022-10-06

  The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.